Literature DB >> 21123302

Intrathecal IgM synthesis in pediatric MS is not a negative prognostic marker of disease progression: quantitative versus qualitative IgM analysis.

C Stauch1, H Reiber, M Rauchenzauner, A Strasak, D Pohl, F Hanefeld, J Gärtner, K M Rostásy.   

Abstract

BACKGROUND: Intrathecal IgM synthesis is reported to be associated with a worse prognosis in adults with multiple sclerosis (MS).
OBJECTIVE: To study the predictive value of intrathecal IgM synthesis for the clinical course of pediatric MS.
METHODS: Seventy children with onset of MS before the age of 16 years and followed for a median period of 10.4 years (range: 0.4-22.8 years) were studied. The two subgroups with (n=44) or without (n=26) intrathecal IgM synthesis were distinguished by a new, very sensitive, evaluation of quantitative analysis in cerebrospinal fluid (CSF)/serum quotient diagrams (Reibergrams). The clinical course and EDSS (Expanded Disability Status Scale) scores at five and ten years were compared with IgM frequencies between both groups with a new statistics program for CSF data.
RESULTS: The cohort of children without intrathecal IgM production had higher numbers of attacks in the first two years and shorter time intervals between first and second attack, although this was not statistically significant (p=0.04, p=0.15 respectively). In addition there was also a trend for girls without intrathecal IgM synthesis to have a higher EDSS score after 10 years compared with the group with IgM synthesis.
CONCLUSION: Intrathecal IgM synthesis is not associated with a more rapid progression of disability in pediatric MS. Reevaluation of data from previous reports about the negative predictive value of intrathecal IgM synthesis in adult MS with a CSF statistics tool show that the apparent contradiction is due to a methodological bias in the qualitative detection of 'oligoclonal' IgM or linear IgM index.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21123302     DOI: 10.1177/1352458510388543

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  7 in total

Review 1.  Multiple sclerosis in children: an update on clinical diagnosis, therapeutic strategies, and research.

Authors:  Amy Waldman; Angelo Ghezzi; Amit Bar-Or; Yann Mikaeloff; Marc Tardieu; Brenda Banwell
Journal:  Lancet Neurol       Date:  2014-09       Impact factor: 44.182

2.  T helper cell- and CD40-dependent germline IgM prevents chronic virus-induced demyelinating disease.

Authors:  Cristina Gil-Cruz; Christian Perez-Shibayama; Sonja Firner; Ari Waisman; Ingo Bechmann; Volker Thiel; Luisa Cervantes-Barragan; Burkhard Ludewig
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-09       Impact factor: 11.205

Review 3.  B cells and antibodies in multiple sclerosis pathogenesis and therapy.

Authors:  Markus Krumbholz; Tobias Derfuss; Reinhard Hohlfeld; Edgar Meinl
Journal:  Nat Rev Neurol       Date:  2012-10-09       Impact factor: 42.937

Review 4.  Intrathecal IgG synthesis: a resistant and valuable target for future multiple sclerosis treatments.

Authors:  Mickael Bonnan
Journal:  Mult Scler Int       Date:  2015-01-08

5.  Kappa Free Light Chains in the Context of Blood Contamination, and Other IgA- and IgM-Related Cerebrospinal Fluid Disease Pattern.

Authors:  Malte Johannes Hannich; Alexander Dressel; Kathrin Budde; Astrid Petersmann; Matthias Nauck; Marie Süße
Journal:  Cells       Date:  2021-03-11       Impact factor: 6.600

6.  Predicting Aggressive Multiple Sclerosis With Intrathecal IgM Synthesis Among Patients With a Clinically Isolated Syndrome.

Authors:  Enric Monreal; Susana Sainz de la Maza; Lucienne Costa-Frossard; Paulette Walo-Delgado; Javier Zamora; José Ignacio Fernández-Velasco; Noelia Villarrubia; Mercedes Espiño; Daniel Lourido; Paloma Lapuente; Inmaculada Toboso; José Carlos Álvarez-Cermeño; Jaime Masjuan; Luisa María Villar
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2021-07-22

7.  Cerebrospinal Fluid IgM Levels in Association With Inflammatory Pathways in Multiple Sclerosis Patients.

Authors:  Roberta Magliozzi; Valentina Mazziotti; Luigi Montibeller; Anna I Pisani; Damiano Marastoni; Agnese Tamanti; Stefania Rossi; Francesco Crescenzo; Massimiliano Calabrese
Journal:  Front Cell Neurosci       Date:  2020-10-16       Impact factor: 5.505

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.